Research & Development
InDevR’s Research & Development team is committed to developing innovative, cutting edge instrumentation and assays for the vaccine development and production industries and for pathogen detection.
Vaccine Development and Production
InDevR’s engineers and scientists are working to create analytical instrumentation and assays to streamline processes and update antiquated methods used throughout the vaccine development and production cycle. The existing Cypher One™ and VaxArray® Influenza product lines are continuing to be expanded upon to have greater application throughout the industry.
Pathogen Detection and Identification
InDevR is developing a new, multiplexed influenza diagnostic (FluChip-8G™) with the goal of bringing a high information content influenza diagnostic closer to patients. The assay is based on simultaneous amplification of 8 genes followed by hybridization to a microarray with sequence specific targets, automated image analysis and automated results interpretation by a Digital Neural Network. Multiplexed analysis of these 8 genes with a same-day assay provides “deep genotyping” in a straightforward, cost effective format. Based on pre-clinical assessment, the assay accurately identifies virus type and subtype, including B lineage (Yamagata or Victoria), The assay is also designed to differentiate HA and NA subtypes, and provide presence/absence indication for key NA antiviral resistance markers.
If cleared by the U.S. Food and Drug Administration, FluChip-8G will enhance clinical diagnosis of influenza in hospitals, urgent care facilities, and clinical laboratories by enabling physicians to rapidly distinguish between seasonal strains and potential pandemic non-seasonal strainbs of the influenza virus, such as H5N1 or H7N9.
The FluChip-8G system will provide an unprecedented level of information about viruses detected in human clinical specimens, without the need for virus isolation. This information will allow physicians to make better informed decisions about treatment options for their patients,” said Dr. Kathy Rowlen, InDevR’s CEO.
Initial development was supported through the NIAID’s SBIR program. Product development is now supported by BARDA (see press release).
Please email us if you would like more information.